Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Surgery Partners (SGRY) EBITDA (2016 - 2025)

Surgery Partners' EBITDA history spans 12 years, with the latest figure at $110.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 13.3% year-over-year to $110.2 million; the TTM value through Dec 2025 reached $389.5 million, up 11.67%, while the annual FY2025 figure was $559.7 million, 13.39% up from the prior year.
  • EBITDA for Q4 2025 was $110.2 million at Surgery Partners, up from $105.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $127.1 million in Q4 2024 and bottomed at $46.4 million in Q1 2023.
  • The 5-year median for EBITDA is $83.7 million (2023), against an average of $85.7 million.
  • The largest annual shift saw EBITDA soared 243.78% in 2021 before it tumbled 53.78% in 2023.
  • A 5-year view of EBITDA shows it stood at $114.8 million in 2021, then fell by 17.94% to $94.2 million in 2022, then grew by 7.64% to $101.4 million in 2023, then rose by 25.35% to $127.1 million in 2024, then decreased by 13.3% to $110.2 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's EBITDA are $110.2 million (Q4 2025), $105.7 million (Q3 2025), and $111.7 million (Q2 2025).